Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand

: Amoury, M.; Bauerschlag, D.; Zeppernick, F.; Felbert, V.; Berges, N.; Fiore, S.D.; Mintert, I.; Bleilevens, A.; Maass, N.; Bräutigam, K.; Meinhold-Heerlein, I.; Stickeler, E.; Barth, S.; Fischer, R.; Hussain, A.F.

Volltext (PDF; )

OncoTarget 7 (2016), Nr.34, S.54925-54936
ISSN: 1949-2553
Zeitschriftenaufsatz, Elektronische Publikation
Fraunhofer IME ()

Triple-negative breast cancer (TNBC) is a heterogeneous disease in which the tumors do not express estrogen receptor (ER), progesterone receptor (PgR) or human epidermal growth factor receptor 2 (HER2). Classical receptor-targeted therapies such as tamoxifen or trastuzumab are therefore unsuitable and combinations of surgery, chemotherapy and/or radiotherapy are required. Photoimmunotheranostics is a minimally invasive approach in which antibodies deliver nontoxic photosensitizers that emit light to facilitate diagnosis and produce cytotoxic reactive oxygen species to induce apoptosis and/or necrosis in cancer cells. We developed a panel of photoimmunotheranostic agents against three TNBC-associated cell surface antigens.